secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001628280-24-009540
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics 2023 net loss $98.4M, cash $234.1M; FHD-909 IND planned Q2 2024
--------------------------------------------------------------------------------

- Net loss $98.4M in 2023 vs $108.9M in 2022; collaboration revenue $34.2M, up from $19.2M.
- Cash $234.1M at Dec 31, 2023; runway into H1 2026.
- FHD-286 AML combo study dose escalation ongoing; first clinical data expected H2 2024.
- Lilly selects FHD-909 (BRM inhibitor) for clinical dev; IND filing Q2 2024 for BRG1-mutated NSCLC.
- Preclinical data for CBP/EP300 degraders at AACR; IND-enabling studies for CBP degrader by end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024009540/0001628280-24-009540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024009540/fhtx-20240307.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-009540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer